drugset

drugset / Trial / NCT04049851

Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients

NCT04049851 ↗

Phase 2 Completed 72 enrolled Center for Research on Filariasis and Other Tropical Diseases, Cameroon

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study aims at evaluating the safety and efficacy of Moxidectin 2 mg in patients with low intensities of microfilariae of Loa loa.

Timeline

Start: 2022-04-07
Primary completion: 2023-07-22
Completion: 2023-07-22

Publications

Wafeu GS, Lepage TM, Campillo JT, Efon-Ekangouo A, Nana-Djeunga HC, Nzune-Toche N, Domche A, Sumo L, Njitchouang GR, Tsasse MAF, Bopda J, Balog YA, Niamsi-Emalio Y, Mbickmen-Tchana S, Talla GK, Kana YSN, Messina FDM, Pion SD, Kuesel AC, Kamgno J, Boussinesq M, Chesnais CB. Safety and Short-term Efficacy of a Single Dose of 2 mg Moxidectin in Loa loa-Infected Individuals: A Double-Blind, Randomized Ivermectin-Controlled Trial With Ascending Microfilarial Densities. Open Forum Infect Dis. 2024 Apr 25;11(7):ofae240. doi: 10.1093/ofid/ofae240. eCollection 2024 Jul.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Ivermectin	Small molecule	150 ug/kg	—
Subject	Moxidectin	Other / unclassified	2 mg	Oral

Indications